Erlander Mark 4
4 · Cardiff Oncology, Inc. · Filed Mar 16, 2023
Insider Transaction Report
Form 4
Erlander Mark
DirectorChief Executive Officer
Transactions
- Award
Stock Options
2023-03-15+482,064→ 1,664,477 totalExercise: $1.72Exp: 2033-03-15→ Common Stock (482,064 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option will vest on March 15, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.